Eli Lilly (NYSE:LLY) agreed to acquire Ajax Therapeutics for up to $2.3b, adding a Type II JAK2 inhibitor program for ...

Eli Lilly and Company and Ajax Therapeutics, Inc. ("Ajax"), a biopharmaceutical company developing next generation JAK inhibitors for patients with myeloproliferative neoplasms (MPNs), today announced ...

Eli Lilly is stepping further into oncology with an agreement to acquire closely held Ajax Therapeutics for up to $2.3 billion in cash, a ...

Clarksville Mayor Joe Pitts plans to end the lease for the Ajax Turner 50+ Center over safety concerns, leaving members and ...

Total consideration reaches up to $2.3 billion via upfront payment plus milestones tied to predefined clinical and regulatory ...

Eli Lilly to acquire Ajax Therapeutics for up to $2.3B, boosting blood cancer pipeline with a Phase 1 JAK2 inhibitor for ...

Wednesday has been a major success story for Netflix’s original programming ever since the debut of its first season in 2022. The series is based on the long-running Addams Family franchise and stars ...

Earn these JavaScript certs to demonstrate mastery of the most in-demand skills for the world’s most-used programming ...

Carragher verdict on Henderson departureJamie Carragher has delivered a firm and deeply reflective assessment of Jordan ...

Ajax deal expands Lilly’s oncology pipeline; Hematology focus adds depth beyond GLP therapies; Healthcare strategy gains ...

Lilly will pay up to $2.3B for Ajax and its AJ1‑11095 myelofibrosis drug; proof‑of‑concept data expected in 2026.

Eli Lilly (LLY) acquires Ajax Therapeutics for $2.3B, adding AJ1-11095, a novel JAK2 inhibitor for myelofibrosis and blood ...